Quinacrine as an Inhibitor of Viral Cysteine Proteases and/or Serine Proteases

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to the use of quinacrine as an inhibitor of viral cysteine and serine proteases, particularly those essential for viral replication in Flaviviridae (such as Zika, Dengue, Yellow Fever, West Nile) and Togaviridae (including Chikungunya and other alphaviruses). By inhibiting these critical viral enzymes, quinacrine can potentially prevent or treat infections caused by single or multiple viruses from these families. The patent covers pharmaceutical compositions and methods of using quinacrine for prophylaxis or therapy of such viral infections.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Zika virus infections in humans and animals
• Therapeutic intervention for Dengue fever
• Prevention and management of Yellow Fever and West Nile virus infections
• Treatment or prevention of Chikungunya and other alphavirus infections
• Prophylactic use for at-risk populations during outbreaks of Flaviviridae or Togaviridae viruses
• Combination therapy for co-infections by multiple viruses from these families
• Development of broad-spectrum antiviral drugs for emerging pathogens in Flaviviridae and Togaviridae

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a potential broad-spectrum antiviral option for a range of dangerous and emerging viruses
• Targets essential viral enzymes, disrupting the virus life cycle and preventing replication
• Offers possible oral, injectable, or inhalable formulations, increasing flexibility of treatment options
• May rapidly repurpose an already approved drug (quinacrine) for new antiviral indications, reducing development time
• Effectiveness against both single and co-infections of multiple viruses, which is valuable in epidemic or pandemic situations
• Can complement or enhance existing antiviral treatments

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to an active ingredient for inhibiting cysteine proteases and serine proteases and, consequently, to a treatment of infections caused by viruses from the group of Flaviviridae and Togaviridae. The invention therefore relates to quinacrine for use for the production of an inhibitor for viral cysteine proteases and/or serine proteases. The invention also relates to quinacrine for use for the production of an inhibitor for cysteine proteases and/or serine proteases of viruses from the family of Flaviviridae and/or Togaviridae.